Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Capital Expenditures (2020 - 2025)

Definitive Healthcare (DH) has disclosed Capital Expenditures for 6 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 60.56% year-over-year to $4.4 million, compared with a TTM value of $16.7 million through Dec 2025, up 35.45%, and an annual FY2025 reading of $16.7 million, up 35.45% over the prior year.
  • Capital Expenditures was $4.4 million for Q4 2025 at Definitive Healthcare, down from $7.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $11.3 million in Q4 2024 and bottomed at -$3.8 million in Q2 2021.
  • Average Capital Expenditures over 5 years is $1.9 million, with a median of $1.0 million recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 122316.67% in 2025, while the deepest fall reached 434.42% in 2025.
  • Year by year, Capital Expenditures stood at $1.2 million in 2021, then plummeted by 289.49% to -$2.3 million in 2022, then surged by 89.69% to -$236000.0 in 2023, then soared by 4870.76% to $11.3 million in 2024, then crashed by 60.56% to $4.4 million in 2025.
  • Business Quant data shows Capital Expenditures for DH at $4.4 million in Q4 2025, $7.3 million in Q3 2025, and -$2.8 million in Q2 2025.